Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.9 USD | -1.67% | -10.20% | -15.71% |
05-17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
05-14 | KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |